Investigating new therapies for a specific type of lung cancer with genetic mutations.
Project 2
This study is looking at a type of lung cancer with a specific gene mutation that makes it more aggressive, and it's testing new drug combinations to see if they can help reduce stress in the cancer cells and improve treatment for patients with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10891396 on NIH RePORTER |
What this research studies
This research focuses on a specific subset of non-small cell lung cancer (NSCLC) that has mutations in the SMARCA4 gene, which are common and associated with aggressive disease. The study aims to explore how these mutations lead to increased DNA stress in cancer cells and how this can be targeted with new drug combinations, particularly those that inhibit the ATR pathway. By understanding the unique characteristics of these tumors, researchers hope to identify effective treatment strategies that could improve outcomes for patients with this type of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific mutations in the SMARCA4 gene.
Not a fit: Patients with non-small cell lung cancer who do not have SMARCA4 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with SMARCA4-mutant NSCLC, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting DNA replication stress in cancer, suggesting that this approach may be effective for SMARCA4-mutant NSCLC.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Barbie, David a — Dana-Farber Cancer Inst
- Study coordinator: Barbie, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.